Journal of Clinical Oncology
Articles in this Issue
Real-world comparison of survival with nivolumab (NIVO) + relatlimab (RELA) vs NIVO + ipilimumab (IPI) in advanced melanoma.
9527 Background: An indirect-treatment (Tx)-comparison (ITC) suggested first-line (1L) NIVO + RELA may have similar efficacy vs NIVO + IPI in clinical tri...
Phase I/IIa clinical study of 4th generation BTK inhibitor HBW-3220 capsules in patients with B-cell malignancies.
e15143 Background: HBW-3220 is in Phase I/IIa trials. It is a reversible 4th generation Bruton’s tyrosine kinase inhibitor (BTKi) effective against BTK wi...
Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).
7530 Background: B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D) are validated targets in MM. GPRC5D is...
First report on the characterization of public and private patients with ovarian cancer in Chile.
e17588 Background: Ovarian cancer (OC) is considered the most aggressive gynecologic cancer. In Chile, the incidence and mortality rate of OC are increasi...
First-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in Chinese patients with unresectable or metastatic melanoma: Results from LEAP-003.
9553 Background: Results of the global, phase 3 LEAP-003 study, showed that lenvatinib (len) + pembrolizumab (pembro) sign...
Dissecting publication timelines: Insights from high-impact oncology journals.
9037 Background: Efficient dissemination of research findings is critical in oncology, where timely access to new knowledge impacts clinical care and outc...
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
3006 Background: During NCI-MATCH (NCT02465060) clinical trial screening, 5961 advanced cancer patients underwent next-generation sequencing to assess eli...
Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with <i>ARID1A</i> -mutated ovarian clear cell carcinoma or endometrial carcinoma.
3102 Background: EZH2 inhibition antitumor activity occurs through various mechanistic pathways in multiple tumor types, including via synthetic lethality...
Driving precision oncology in lung cancer: Patient stratification through comprehensive genomic profiling.
8070 Background: Next Generation Sequencing (NGS)-guided targeted therapy is a standard practice in lung cancer, as recommended by professional guidelines...
Quantifiable renal lesion diagnostic MDCT enhancement criteria for pathology prediction and clinical correlation.
e16502 Background: Contrast-enhanced MDCT phases are proven to help differentiate renal solid tumors. However, obtaining four sequences for all patients i...
PD-1/PD-L1 inhibitors as second-line therapy for advanced, unresected esophageal squamous-cell carcinoma: A series of patient-level meta-analyses.
e16052 Background: Patients with esophageal squamous cell carcinoma (ESCC) who fail definitive treatment are candidates for second-line therapy. They ofte...
Analysis of evidence in NCCN harmonized guidelines for sub-Saharan Africa.
1510 Background: The National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for Sub-Saharan Africa (SSA) have emerged as leading cancer treatm...
Neuroendocrine neoplasm: A 10-year retrospective review of a single-center experience.
e16349 Background: Neuroendocrine neoplasm (NENs) are uncommon, diverse tumors with different phenotypes & behaviors. This study aims to examine the d...
Combined PD-L1 expression and PD-1+ CD8 T cells to predict immunotherapy outcomes in esophageal squamous cell carcinoma.
4053 Background: Esophageal squamous cell carcinoma (ESCC), the predominant subtype of esophageal cancer in Asia, remains a challenging disease with poor...
Exploration of the new classification of hormone receptor-positive breast cancer: Based on the genomic landscape of 2111 early to mid-stage Asian patients.
596 Background: The molecular classification of breast cancer using omics data has led to varied prognoses; however, with the increase of targeted therapy...
Real-world clinical outcome of trastuzumab derutexcan (T-DXd) in metastatic breast cancer.
e23323 Background: Trastuzumab derutexcan (T-DXd) is an anti-HER2 antibody-drug conjugate (ADC) which showed promises in patients (pts) with metastatic br...
Effect of allostatic load and measures of segregation on cancer detection and false positive rate after screening mammography.
565 Background: Allostatic load (AL), a cumulative stress measure and residential segregation (MRSs) have been associated with breast cancer (BC) outcomes...
Integrating early palliative care in advanced sarcoma patients for enhanced quality of life: The SARQUALITY study.
TPS11587 Background: Patients with advanced cancer may experience physical and psychological symptoms impacting health-related (HRQOL). The World Health O...
Correlation between the number of circulating epithelial tumor cells (CETCs/CTCs) and circulating tumor DNA (ctDNA) in patients with colorectal cancer.
e15586 Background: The correlation between CETCs/CTCs and ctDNA has gained significant attention in cancer research, particularly in patients with colorec...
Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.
e15084 Background: Single gene assays constitute the most common modality used to detect actionable genomic biomarkers in cancer tissue in Australian clin...
Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: 1 year updated results from UC-001, a single-center, single-arm, phase II trial.
4525 Background: For patients (pts) with recurrent or stage IV non-clear cell renal cell carcinoma (nccRCC), the current guidelines recommend participatio...
Development and fairness assessment of machine learning models for predicting 30-day readmission after lung cancer surgery.
1532 Background: Predicting post-surgical readmissions is essential for improving patient outcomes and reducing healthcare costs. While machine learning (...
Real-world socioeconomic disparities in cancer outcomes: Insights from a federally qualified health center.
e23099 Background: Despite advancements in cancer care, socioeconomic barriers continue to create significant disparities in patient outcomes. Factors suc...
Clinical outcome, treatment modalities and overall survival in microsatellite stable and unstable colon cancers: A National Cancer Database (NCDB) analysis.
e15702 Background: Colon cancers (CC) can be classified as microsatellite stable (MSS) and microsatellite instability-high (MSI-H) cancers. This study aim...
Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial.
6017 Background: HPV-negative head and neck squamous cell carcinoma (HNSCC) is an aggressive disease characterized by high recurrence, metastasis (R/M), a...